IE87241B1 - Prevention and/or treatment of neurodegenerative disease - Google Patents
Prevention and/or treatment of neurodegenerative disease Download PDFInfo
- Publication number
- IE87241B1 IE87241B1 IE20180146A IE20180146A IE87241B1 IE 87241 B1 IE87241 B1 IE 87241B1 IE 20180146 A IE20180146 A IE 20180146A IE 20180146 A IE20180146 A IE 20180146A IE 87241 B1 IE87241 B1 IE 87241B1
- Authority
- IE
- Ireland
- Prior art keywords
- composition
- composition according
- zeaxanthin
- omega
- fatty acid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/60—Fish, e.g. seahorses; Fish eggs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Marine Sciences & Fisheries (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1720119.5A GB201720119D0 (en) | 2017-12-04 | 2017-12-04 | Prevention and/or treatment of neurodegenerative disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IE20180146A1 IE20180146A1 (en) | 2019-06-12 |
| IE87241B1 true IE87241B1 (en) | 2021-07-07 |
Family
ID=60950313
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IE20180146A IE87241B1 (en) | 2017-12-04 | 2018-05-15 | Prevention and/or treatment of neurodegenerative disease |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US10835509B2 (https=) |
| EP (2) | EP3644979B1 (https=) |
| JP (2) | JP7824729B2 (https=) |
| KR (1) | KR20200095452A (https=) |
| AU (1) | AU2018379644B2 (https=) |
| BR (1) | BR112020005132A2 (https=) |
| CA (1) | CA3071786C (https=) |
| ES (1) | ES3047101T3 (https=) |
| GB (2) | GB201720119D0 (https=) |
| IE (1) | IE87241B1 (https=) |
| MX (1) | MX2020002458A (https=) |
| RU (1) | RU2020111305A (https=) |
| SG (1) | SG11202000786RA (https=) |
| WO (1) | WO2019110951A1 (https=) |
| ZA (1) | ZA202000558B (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR3106957B1 (fr) * | 2020-02-07 | 2024-05-03 | Abdelhadi Zahouani | Composition alimentaire pour stimuler la fonction cognitive et prevenir et limiter le declin cognitif et la demence chez des sujets adultes ou chez des sujets ages denutris |
| US12076299B2 (en) * | 2020-02-20 | 2024-09-03 | Arjuna Natural Pvt Ltd | Composition and method to enhance cognitive support and brain health |
| KR20240008846A (ko) * | 2021-05-17 | 2024-01-19 | 오노 야꾸힝 고교 가부시키가이샤 | 인지 기능을 개선하기 위한 조성물 |
| JPWO2024143060A1 (https=) * | 2022-12-26 | 2024-07-04 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050163873A1 (en) | 2004-01-14 | 2005-07-28 | Robert Ritch | Methods and formulations for treating glaucoma |
| US8324276B2 (en) * | 2005-01-24 | 2012-12-04 | Pronova Biopharma Norge As | Fatty acid composition for treatment of alzheimer's disease and cognitive dysfunction |
| WO2006116755A2 (en) * | 2005-04-28 | 2006-11-02 | Trustees Of Tufts College | Synergitic effects of docosahexaenoic acid (dha) and carotenoid absorption of cognitive function |
| PL2219478T3 (pl) * | 2007-12-17 | 2017-10-31 | Newtricious Bv | Sposób wytwarzania funkcjonalnego produktu spożywczego na bazie żółtka jaja i produkty otrzymywane tym sposobem |
| GB201014340D0 (en) | 2010-08-27 | 2010-10-13 | Piraee Mahmood | Nutritional supplement formulation comprising saffron and resveratrol |
| HUE038813T2 (hu) * | 2011-07-07 | 2018-11-28 | Howard Foundation Holdings Ltd | Eljárás rontó káprázás javítására |
| DE212013000066U1 (de) * | 2012-07-19 | 2014-09-25 | U.S. Nutraceuticals Llc Dba Valensa International | Krillöl und reagierte Astaxanthinzusammensetzung |
| GB201300055D0 (en) | 2013-01-03 | 2013-02-20 | Howard Foundation Holdings Ltd | Identifying subjects in need of treatment |
| US20140187648A1 (en) * | 2013-01-03 | 2014-07-03 | Howard Foundation Holdings Ltd. | Identifying Subjects in Need of Treatment |
| MX2015013624A (es) * | 2013-03-28 | 2016-06-10 | Omniactive Health Technologies Ltd | Efecto neuroprotector de carotenoides en el cerebro. |
| JP6178761B2 (ja) | 2013-07-10 | 2017-08-09 | ライオン株式会社 | 内服剤 |
| US20190314442A1 (en) * | 2016-02-22 | 2019-10-17 | Newtricious B.V. | Composition for the prevention or treatment of neurodegenerative diseases |
-
2017
- 2017-12-04 GB GBGB1720119.5A patent/GB201720119D0/en not_active Ceased
-
2018
- 2018-05-10 MX MX2020002458A patent/MX2020002458A/es unknown
- 2018-05-10 CA CA3071786A patent/CA3071786C/en active Active
- 2018-05-10 ES ES18725605T patent/ES3047101T3/es active Active
- 2018-05-10 AU AU2018379644A patent/AU2018379644B2/en active Active
- 2018-05-10 SG SG11202000786RA patent/SG11202000786RA/en unknown
- 2018-05-10 RU RU2020111305A patent/RU2020111305A/ru unknown
- 2018-05-10 BR BR112020005132-2A patent/BR112020005132A2/pt not_active Application Discontinuation
- 2018-05-10 KR KR1020207007980A patent/KR20200095452A/ko active Pending
- 2018-05-10 GB GB1807590.3A patent/GB2568986B/en active Active
- 2018-05-10 EP EP18725605.2A patent/EP3644979B1/en active Active
- 2018-05-10 JP JP2020521460A patent/JP7824729B2/ja active Active
- 2018-05-10 WO PCT/GB2018/051255 patent/WO2019110951A1/en not_active Ceased
- 2018-05-10 EP EP25186112.6A patent/EP4599891A3/en active Pending
- 2018-05-15 IE IE20180146A patent/IE87241B1/en unknown
- 2018-05-15 US US15/980,083 patent/US10835509B2/en active Active
-
2020
- 2020-01-28 ZA ZA2020/00558A patent/ZA202000558B/en unknown
-
2025
- 2025-10-31 JP JP2025184568A patent/JP2026016698A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| GB201720119D0 (en) | 2018-01-17 |
| GB2568986A (en) | 2019-06-05 |
| IE20180146A1 (en) | 2019-06-12 |
| MX2020002458A (es) | 2020-07-20 |
| CA3071786A1 (en) | 2019-06-13 |
| EP3644979A1 (en) | 2020-05-06 |
| EP4599891A3 (en) | 2025-10-22 |
| SG11202000786RA (en) | 2020-06-29 |
| AU2018379644A1 (en) | 2020-03-19 |
| NZ761512A (en) | 2024-01-26 |
| WO2019110951A1 (en) | 2019-06-13 |
| GB2568986B (en) | 2019-12-18 |
| AU2018379644B2 (en) | 2024-02-08 |
| CA3071786C (en) | 2023-11-14 |
| ES3047101T3 (en) | 2025-12-03 |
| ZA202000558B (en) | 2021-10-27 |
| RU2020111305A (ru) | 2022-01-10 |
| JP2026016698A (ja) | 2026-02-03 |
| EP4599891A2 (en) | 2025-08-13 |
| EP3644979B1 (en) | 2025-08-06 |
| US20190167624A1 (en) | 2019-06-06 |
| GB201807590D0 (en) | 2018-06-27 |
| JP2021505527A (ja) | 2021-02-18 |
| JP7824729B2 (ja) | 2026-03-05 |
| US10835509B2 (en) | 2020-11-17 |
| KR20200095452A (ko) | 2020-08-10 |
| BR112020005132A2 (pt) | 2020-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2955713T3 (es) | Agente de mejora de la función visual, y método para mejorar la función visual | |
| US20130108706A1 (en) | Dietary formulations | |
| IE87241B1 (en) | Prevention and/or treatment of neurodegenerative disease | |
| CN103533921A (zh) | 用于治疗神经外伤的方法 | |
| JP6375296B2 (ja) | 脳機能改善用内服組成物、脳内アミロイドβ蓄積抑制用内服組成物、脳機能改善用食品組成物及び脳内アミロイドβ蓄積抑制用食品組成物 | |
| US10881638B2 (en) | Eye health composition | |
| CN101327199A (zh) | 作为抗高血压药的类胡萝卜素 | |
| TW201434470A (zh) | 提昇認知功能及肌肉功能之營養組合物及方法 | |
| US12053437B2 (en) | Eye health supplement | |
| NZ761512B2 (en) | Prevention and/or treatment of neurodegenerative disease | |
| WO2013086330A1 (en) | Nutritional compositions comprising curcumin and docosahexaenoic acid for improving cognition | |
| JP3192948U (ja) | Ｄｈａ、ｅｐａにアスタキサンチンを含有した機能性食品を含有する錠剤又はカプセル錠剤。 | |
| HK40130790A (en) | Prevention and/or treatment of neurodegenerative disease | |
| HASBAL-CELIKOK | NUTRITIONAL SUPPLEMENTS FOR BRAIN HEALTH | |
| Parker | Glaucoma-evidence for adjunctive management: Part 1 cellular and physiological level | |
| US20210228557A1 (en) | Therapeutic compositions comprising coenzyme q10 | |
| Gillingham | Omega-3 fatty acids and the menopausal transition: clinical efficacy in depression and beyond | |
| Welge-Luessen et al. | The role of micronutrients in the treatment of vitreous floaters | |
| JP2016008214A (ja) | Ｄｈａ、ｅｐａにアスタキサンチンを含有した機能性食品、及び錠剤又はカプセル錠剤。 |